Asia-Pacific Cancer It is anticipated that the Biomarker Testing Market will experience a significant compound annual growth rate (CAGR) of 12.58% during the review period.
The term ""cancer biomarker testing"" denotes the detection of biological markers, such as molecules or genes, in blood, tissues, or other physiological fluids to ascertain the presence, progression, or risk of cancer. Early identification, diagnosis, prognosis, and treatment selection can be facilitated by these biomarkers, which can offer critical insights into the genetic, genomic, and cellular characteristics of a tumour. Biomarker testing enables clinicians to comprehend the distinctive characteristics of a patient's malignancy, thereby enabling the development of more personalised treatment strategies. Biomarkers in cancer may be genetic (e.g., DNA mutations), proteomic (protein-related), or epigenetic. Next-generation sequencing (NGS), polymerase chain reaction (PCR), and immunohistochemistry comprise the testing procedures. Cancer biomarker testing is particularly beneficial for targeted therapies and immunotherapies, as it identifies individuals who are most likely to benefit from specific treatments based on the genetic composition of their tumours. Biomarker testing contributes to the monitoring of disease development, the detection of recurrences, and the evaluation of treatment response, in addition to guiding medication. Biomarker testing becomes an increasingly critical instrument for enhancing cancer care outcomes and fostering precision medicine as cancer research advances.
Market Segmentation
The Asia-Pacific cancer biomarker testing market has been segmented into product and services based on type. The services segment is the fastest-growing segment during the forecast period (2024-2032), while the product segment held the greatest market share in 2023.
The Asia-Pacific cancer biomarker testing market has been segmented into single gene testing and multiple gene testing, based on the type of testing. In 2023, the multiple gene testing segment occupied the largest market share and is expected to experience the most rapid growth during the forecast period (2024-2032).
The global Asia-Pacific Cancer biomarker testing market has been segmented into the following countries: China, India, Japan, South Korea, Singapore, Australia, New Zealand, Hong Kong, Thailand, and Taiwan. The India segment is the fastest-growing segment during the forecast period (2024-2032), while the China segment held the largest market share in 2023.
Major Players
The foremost market participants are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., Illumina, Inc., Pacific Biosciences, Qiagen N.V., and Oxford Nanopore Technologies Plc.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook